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Abstract
Urinary tract infections (UTIs) due to fluoroquinolone-insusceptible Escherichia coli have be-
come increasingly common in recent years. We investigated the potential relationships between
clinical measures to combat fluoroquinolone-insusceptible E. coli and experimental analyses on
E. coli isolates. Over a 14-year period from 1994 through 2007, a total of 828 E. coli isolates
were collected from patients (one isolate per patient) with UTI at the urology ward of Okayama
University Hospital. We analyzed the mutations in quinolone resistance-determining regions of
DNA gyrase (gyrA) and topoisomerase IV (parC). The production of biofilm by these isolates
was also examined and the associated medical records were retrospectively reviewed. Seven
of 189 (3.7%) strains from uncomplicated UTIs and 82 of 639 (12.8%) strains from compli-
cated UTIs were insusceptible to fluoroquinolones. Amino acid replacements of type II topoi-
somerases were frequently observed at positions 83 and 87 in GyrA and at positions 80 and
84 in ParC. No significant difference in the biofilm-forming capabilities was observed between
fluoroquinolone-susceptible and -insusceptible E. coli. Our study suggests that biofilm formation
of fluoroquinolone-insusceptible E. coli isolates is not a major mechanism of resistance in patients
with UTI.
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Urinary tract infections (UTIs) due to ﬂuoroquinolone-insusceptible Escherichia coli have become 
increasingly common in recent years.  We investigated the potential relationships between clinical 
measures to combat ﬂuoroquinolone-insusceptible E. coli and experimental analyses on E. coli isolates.  
Over a 14-year period from 1994 through 2007,  a total of 828 E. coli isolates were collected from 
patients (one isolate per patient) with UTI at the urology ward of Okayama University Hospital.  We 
analyzed the mutations in quinolone resistance-determining regions of DNA gyrase (gyrA) and topoi-
somerase IV (parC).  The production of bioﬁlm by these isolates was also examined and the associated 
medical records were retrospectively reviewed. Seven of 189 (3.7ｵ) strains from uncomplicated UTIs 
and 82 of 639 (12.8ｵ) strains from complicated UTIs were insusceptible to ﬂuoroquinolones.  Amino 
acid replacements of type II topoisomerases were frequently observed at positions 83 and 87 in GyrA 
and at positions 80 and 84 in ParC.  No signiﬁcant diﬀerence in the bioﬁlm-forming capabilities was 
observed between ﬂuoroquinolone-susceptible and -insusceptible E. coli.  Our study suggests that bio-
ﬁlm formation of ﬂuoroquinolone-insusceptible E. coli isolates is not a major mechanism of resistance 
in patients with UTI.
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scherichia coli is one of the major causes of uri-
nary tract infections (UTIs).  Fluoroquinolones 
are often used as potent antimicrobial agents against 
E. coli and other pathogens in Japan as well as in other 
Asian countries and Europe.  As a result,  there have 
been reports in Japan,  Korea [1],  and Europe [2] on 
the emergence of E. coli strains with increasing resis-
tance to ﬂuoroquinolones.  Resistance to ﬂuoroquino-
lones has also been observed in other bacteria,  such 
as Neisseria gonorrhoeae.  Thus the widespread use of 
ﬂuoroquinolones has resulted in ﬂuoroquinolone-re-
sistant N. gonorrhoeae,  which accounts for 80ｵ to 
90ｵ of N. gonorrhoeae infections,  particularly in Asia 
[3].  Therefore,  cefotriaxone,  cefodizime,  and spec-
tinomycin are recommended instead of ﬂuoroquinolo-
nes for the treatment of gonorrheal infections in 
Japan [4].
　 There have been numerous reports on the mecha-
E
Acta Med.  Okayama,  2009
Vol.  63,  No.  5,  pp.  263ﾝ272
CopyrightⒸ 2009 by Okayama University Medical School.
Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/
Received April 28, 2009 ; accepted June 9, 2009.
 ＊Corresponding author. Phone : ＋81ﾝ86ﾝ235ﾝ7287; Fax : ＋81ﾝ86ﾝ231ﾝ3986
E-mail : kariyama@md.okayama-u.ac.jp (R. Kariyama)
1
Wada et al.: Experimental and Clinical Studies on Fluoroquinolone-insusceptibl
Produced by The Berkeley Electronic Press, 2009
nism of ﬂuoroquinolone resistance in E. coli [5,  6].  
There is an urgent need to stop the spread of resis-
tance by prompt implementation of clinical measures.  
In the present study,  we investigated the potential 
relationships between clinical measures to combat 
ﬂuoroquinolone-insusceptible (intermediate or resis-
tant) E. coli and experimental analyses on E. coli iso-
lates.  Over a 14-year period from 1994 through 2007,  
a total of 828 E. coli isolates were collected from 
patients with UTI at the urology ward of Okayama 
University Hospital.  We analyzed the prevalence and 
the mutations in quinolone resistance-determining 
regions (QRDRs) of DNA gyrase (gyrA) and topoi-
somerase IV (parC) and antimicrobial resistance.  In 
addition,  the production of bioﬁlm by these isolates 
was examined and the associated medical records were 
retrospectively reviewed.
Materials and Methods
　 Clinical samples and bacterial isolates.
The subjects were UTI patients who were seen at the 
outpatient and inpatient departments (wards) of the 
Urology Clinic of Okayama University Hospital 
between 1994 and 2007.  The patients with pyuria 
(WBCｧ5/HPF) and bacteriuria (bacteriaｧ1.0×
104 CFU/ml) were included in this study.  There were 
828 strains of E. coli which were isolated from the 
urine of these patients.  If multiple strains were iso-
lated in 1 patient,  the bacterial strain with the lower 
susceptibility was selected and established as the iso-
lated strain.  Then the strains,  from which E. coli was 
isolated again in the same patient for follow-up,  were 
excluded.
　 Midstream urine and catheter urine were collected 
from male and female subjects.  The samples were 
inoculated onto CLED (cysteine-,  lactose-,  and elec-
trolyte- deﬁcient) agar (Becton Dickinson,  Franklin 
Lakes,  NJ,  USA) and cultured for 48h at 37℃.  In 
the strains which formed colonies,  bacteria were 
conﬁrmed to be E. coli using the rapid ID32 Strep 
system (bioMérieux,  Marcy IʼEtoile,  France).  The 
strains were stored in Casitone-based complex medium 
at room temperature.  Then the following methods 
were used to examine their characteristics.
　 Antimicrobial susceptibility testing. The 
minimal inhibitory concentrations (MICs) of antimi-
crobial agents were measured for 79 of 89 strains of 
ﬂuoroquinolone-insusceptible E. coli.  A broth microdi-
lution method was used according to the guidelines of 
the Clinical Laboratory Standards Institute [7].  The 
antimicrobial agents for which the MICs were mea-
sured were ampicillin,  cefazolin,  cefozopran,  minocy-
cline,  imipenem,  gentamycin,  and ﬂuoroquinolones 
(oﬂoxacin,  norﬂoxacin,  levoﬂoxacin,  sparﬂoxacin,  
ciproﬂoxacin,  tosuﬂoxacin,  and sitaﬂoxacin).  Fluoro-
quinolone-insusceptible E. coli strains were deﬁned as 
those with oﬂoxacin MICs ofｧ4µg/ml according to 
the standards of the Clinical Laboratory Standards 
Institute [8].
　 Review of clinical backgrounds of patients.
A retrospective examination was performed on the 
clinical backgrounds of patients in whom E. coli was 
isolated by using their medical records.  The following 
were examined: age,  sex,  underlying diseases of the 
urinary tract,  whether or not catheterization was 
performed,  history of UTI,  use of antimicrobial 
agents before bacterial isolation,  and therapeutic 
course.  The cases were classiﬁed into complicated 
UTI and uncomplicated UTI depending on the pres-
ence or absence of underlying diseases.  The isolation 
rates of ﬂuoroquinolone-insusceptible E. coli were 
compared by the χ2-test.
　 DNA sequencing (amino acid replacements in 
type II topoisomerases). In the isolated ﬂuoro-
quinolone-insusceptible E. coli,  direct sequencing was 
performed to analyze the mutations in QRDRs of DNA 
gyrase and topoisomerase IV.  Then the amino acid 
replacements were determined at those sites.  Nine 
strains of ﬂuoroquinolone-susceptible E. coli were 
randomly selected and used as the control strains.
　 The samples were cultured in a CLED medium for 
24h.  The resulting E. coli colonies were picked with 
sterilized toothpicks.  They were shaken in microtubes 
(volume,  1.5ml) with 50µl of 7.5ｵ Chelex-100 solu-
tion (Bio-Rad Laboratories,  Hercules,  CA,  USA) in 
distilled water,  and were heated at 100℃ for 10min 
to prepare crude genomic DNA lysates.  The mixture 
was held for approximately 10 sec at room tempera-
ture and then centrifuged at 10,000×g for 1min.  
The supernatant (5µl) was collected,  and the ﬁrst 
PCR was performed (Table 1).  The reaction solution 
was puriﬁed using a QIAquick PCR Puriﬁcation Kit 
(QIAGEN,  Valencia,  CA,  USA).  The DNA concen-
tration of the puriﬁed product was measured with a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop 
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Technologies,  Wilmington,  DE,  USA).  The puriﬁed 
product with 8µg of DNA was used in the second PCR 
for direct sequencing (Table 1),  and a Big Dye 
Terminator Kit (Applied Biosystems Japan,  Tokyo,  
Japan) was used to perform ﬂuorescent labeling.  The 
second reaction solution was ethanol precipitated,  and 
ethanol was evaporated at 80℃.  The resulting prod-
uct was dehydrated and stored at 4℃.  The dried 
PCR product was dissolved in 10µl of Hi-Di forma-
mide,  and then sequencing was performed.  An ABI 
PRISM® 3100 sequencer (Biosystems) at the Central 
Research Laboratory,  Okayama University Medical 
School was used to decode the base sequences.  The 
obtained data were analyzed using BLAST databases 
at the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov).  The standard strain,  E. 
coli K12,  was used as the control,  and amino acid 
replacements of type II topoisomerases were exam-
ined.
　 Microplate assay for assessment of bioﬁlm-
forming capabilities. The bioﬁlm-forming capa-
bilities were tested in 81 of 89 strains of ﬂuoroqui-
nolone-insusceptible E. coli and 40 randomly selected 
strains of ﬂuoroquinolone-susceptible E. coli.  Each E. 
coli strain was cultured at 37℃ for 48h in a 96-well 
microplate (MBEC BioProducts,  Edmonton,  Alberta,  
Canada) which was ﬁlled with artiﬁcial urine as in the 
report by Minuth et al.  [9].  Bioﬁlm formed on the peg 
surface in each well was stained with 2ｵ crystal vio-
let and eluted in 95ｵ ethanol.  Then absorbance was 
measured at 570nm using a model 680 microplate 
reader (Bio-Rad).  This procedure was repeated 3 
times for each strain,  and the arithmetic mean of the 
absorbance was used as an indicator of the bioﬁlm-
forming capabilities.  The Mann-Whitney U test was 
used to compare the bioﬁlm-forming capabilities 
between these 2 groups.  All results were considered 
statistically signiﬁcant at the p＜0.05 level.
Results
　 E. coli isolates and antimicrobial susceptibil-
ity testing. In the period between 1994 and 2007,  
a total of 828 strains of E. coli were isolated from 
midstream urine and catheter urine.  According to the 
MICs of oﬂoxacin (MICｧ4µg/ml),  89 E. coli strains 
(10.7ｵ) were classiﬁed as ﬂuoroquinolone-insuscepti-
ble.  Fig.  1 shows the annual changes of isolation 
frequency of ﬂuoroquinolone-insusceptible E. coli and 
the percentage of ﬂuoroquinolone-insusceptible E. coli 
among the total isolated E. coli.  In our study,  ﬂuoro-
quinolone-insusceptible E. coli was ﬁrst isolated in 
1994,  and its isolation frequency and its percentage 
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Table 1　 PCR primers and conditions used in the direct sequence method
Primer
speciﬁcity
Primer sequences
Product
length
[bp]
PCR conditions
Initial
denaturation
Cycling Cycle
Final
extension
DNA gyrase A
gene (gyrA)
1st PCR
F: 5ʼ-GAGGAAGAGCTGAAGAGCTCC-3ʼ
376
5 min,  94℃
1min, 94℃; 1min, 55℃; 1min, 72℃ 25 7min, 72℃
R: 5ʼ-CGAGATCGGCCATCAGTTC-3ʼ
2nd PCR F: 5ʼ-GAGGAAGAGCTGAAGAGCTCC-3ʼ － 30sec, 95℃; 4min, 60℃ 30 －
Topoisomerase
IV gene
(parC)
1st PCR
F: 5ʼ-AAACCTGTTCAGCGCCGCATT-3ʼ
395
5 min, 95℃
1min, 94℃; 1min, 55℃; 1min, 72℃ 25 7min, 72℃
R: 5ʼ-GTGGTGCCGTTAAGCAAA-3ʼ
2nd PCR F: 5ʼ-AAACCTGTTCAGCGCCGCATT-3ʼ － 30sec, 95℃; 4min, 60℃ 30 －
(%)
3
6
9
12
15
ｽ94 ｽ98 ｽ00 ｽ02 ｽ06ｽ04ｽ96 (year)
5
10
15
20
25
Number of 
patients
Fig. 1　 Annual changes in the incidence of UTI due to ﬂuoroqui-
nolone-insusceptible E. coli.
lines: Number of patients with UTI due to ﬂuoroquinolone-
insusceptible E. coli. Percentage of ﬂuoroquinolone-insuscep-
tible E. coli among the total isolated E. coli.
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tended to increase annually beginning in 2000.  In 
2006 and 2007,  approximately 20ｵ of the total E. coli 
strains isolated from urine were ﬂuoroquinolone-
insusceptible E. coli.
　 The measurement of MICs of other antimicrobial 
agents showed that ﬂuoroquinolone-insusceptible E. coli 
was highly susceptible to cefozopran and imipenem.  
Their MIC90s were both 0.5µg/ml (Fig.  2).  The 
MICs of oﬂoxacin showed wide variabilities among 
strains.  There tended to be correlations between 
oﬂoxacin MICs and the MICs of other ﬂuoroquinolo-
nes (Fig.  3).  For sitaﬂoxacin,  the MICs of all 79 
strains tested wereｦ2µg/ml.  Among these strains,  
the MICs of 64 strains (81.0ｵ) wereｦ0.5µg/ml,  and 
those of 13 strains (16.5ｵ) and 2 strains (2.5ｵ) were 
1µg/ml and 2µg/ml,  respectively.  When these MICs 
were compared with those of other ﬂuoroquinolones,  
the high eﬀectiveness was conﬁrmed in vitro.
　 Clinical backgrounds. Of 189 strains of E. 
coli isolated from uncomplicated UTIs,  7 strains 
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Fig. 2　 Cumulative percentages of ﬂuoroquinolone-insusceptible 
E. coli strains at MICs (µg/ml) of several antibiotics except ﬂuoro-
quinolones.  The MIC90 values of ampicillin,  cefazoline,  cefozo-
pran,  imipenem, minocycline and gentamycin were 64,  8,  0.5,  
0.5,  32 and 32µg/ml,  respectively.
lines : ampicillin　　 cefazolin　　 cefozopran 
imipenem　　 minocycline　　 gentamycin
5 13 18 6 1 1 1 1
17 3 1 1 1 2 6 6
2 1 3 5 5 2 3 10
3 2 2 12 2 6 11 3
3 12 13 1 1 14 3
4 13 4 5 3
4 2
ｧ128
64
32
16
8
4
2
1
ｦ0.5
ｦ0.5 1 2 4 8 16 32 64 ｧ128 ｦ0.5 1 2 4 8 16 32 64 ｧ128 ｦ0.5 1 2 4 8 16 32 64 ｧ128
ｦ0.5 1 2 4 8 16 32 64 ｧ128 ｦ0.5 1 2 4 8 16 32 64 ｧ128 ｦ0.5 1 2 4 8 16 32 64 ｧ128
2 1
1 1 6 5 1
8 11 1 1 10 18 17 7 1
19 8 6 1 2
3 4 2 2 8
3 1 4 1
2 1 1 1
3 4 6
ｧ128
64
32
16
8
4
2
1
ｦ0.5 8 25 16 15
CA B
FED
Fig. 3　 Correlations between MICs (µg/ml) of oﬂoxacin (horizontal) and other ﬂuoroquinolones (vertical) for ﬂuoroquinolone-insusceptible 
E. coli strains (n＝79).  A,  norﬂoxacin; B,  levoﬂoxacin; C,  sparﬂoxacin; D,  ciproﬂoxacin; E,  tosuﬂoxacin; F,  sitaﬂoxacin.  MICs of 
tosuﬂoxacin (ｧ64µg/ml) could not be measured due to insolubility.
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(3.7ｵ) were ﬂuoroquinolone-insusceptible E. coli.  Of 
the 639 strains of E. coli isolated from complicated 
UTIs,  82 strains (12.8ｵ) were ﬂuoroquinolone-
insusceptible E. coli.  The analysis by the χ2-test indi-
cated that the isolation rate of ﬂuoroquinolone-insus-
ceptible E. coli from complicated UTIs was 
signiﬁcantly higher than that from uncomplicated 
UTIs.
　 Table 2 shows the clinical backgrounds of patients 
with UTI whose causative agent was ﬂuoroquinolone-
insusceptible E. coli.  The male to female ratio was 
42:47,  and thus the diﬀerence between the number of 
male and female subjects was not signiﬁcant.  The ratio 
of outpatients to inpatients was 58:31,  indicating that 
ﬂuoroquinolone-insusceptible E. coli was isolated more 
often in outpatients than inpatients.  Urethral cathe-
ters were placed in 26 patients (29.2ｵ),  and clean 
intermittent self-catheterization was performed in 14 
patients (15.7ｵ).  There were 66 patients (74.2ｵ) 
who had a previous history of UTI before ﬂuoroqui-
nolone-insusceptible E. coli was isolated.  With respect 
to underlying diseases,  neurogenic bladder (39.0ｵ) 
was seen most often,  followed by malignant diseases 
(26.8ｵ) (such as prostate cancer and bladder cancer),  
and vesico-vaginal or vesico-rectal ﬁstula (13.4ｵ).  
There were 21 patients (23.6ｵ) who had not been 
administered any antimicrobial agents in the two-year 
period prior to the isolation of ﬂuoroquinolone-insus-
ceptible E. coli.  There were 68 patients (76.4ｵ) who 
had been administered some type of antimicrobial 
agent.  Among the 68 patients,  48 (70.6ｵ) had been 
administered ﬂuoroquinolones.  When the selection 
was limited to a two-week period prior to the bacterial 
isolation,  there were 26 patients (29.2ｵ) who had a 
history of being administered antimicrobial agents.  Of 
these patients,  20 (76.9ｵ) had been administered 
ﬂuoroquinolones.
　 Fig.  4 shows the eﬃcacy of treatments and out-
comes among these patients.  A total of 49 patients 
were administered cephems,  and 43 of these patients 
(87.8ｵ) recovered from their UTIs.  Administration 
of penicillins,  penems,  carbapenems,  minocycline,  
sulfamethoxazole-trimethoprim,  and aminoglycosides 
led to complete recovery or a lessening of symptoms,  
and all urine cultures were negative after these treat-
ments,  in addition,  most of urinalysis results 
improved after these treatments.  Among the patients 
administered ﬂuoroquinolones,  many had urine cul-
tures and urinalysis results that did not improve,  and 
follow-ups were not possible in others.  There were 
patients who selected urethral catheterization or clean 
intermittent self-catheterization rather than adminis-
trations of antimicrobial agents among complicated 
UTI patients in whom ﬂuoroquinolone-insusceptible E. 
coli was isolated and in whom clinical symptoms (such 
as fever or pain) were very limited.  There were 16 
patients (18.0ｵ) in whom antimicrobial agents were 
not used,  and spontaneous resolution was observed in 
267Quinolone-insusceptible Escherichia coliOctober 2009
Table 2　 Backgrounds of the patients with UTI due to ﬂuoroqui-
nolone-insusceptible E. coli (n＝89)
Sex: male/female 42/47
Age: median±SD (range) 63±19 (8 to 86)
Outpatient/Inpatient 58/31
Catheterization 26/89 (29.2%)
Self-catheterization 14/89 (15.7%)
Repeated UTI: yes/no 66/22 (unclear: 1)
Underlying diseases of the patients with complicated UTI (n＝82)
　　Neurogenic bladder 32 (39.0%)
　　Malignancy 22 (26.8%)
　　Fistula (vagina,  rectum) 11 (13.4%)
　　Others 17 (20.7%)
Administration of the antimicrobial agent before bacterial isolation
　　Prescribed for the last 2 years 68/89 (76.4%)
　　　Prescription of  ﬂuoroquinolones 48/68 (70.6%)
　　Just before isolation (for last 2 weeks) 26/89 (29.2%)
　　　Prescription of  ﬂuoroquinolones 20/26 (76.9%)
　　No prescription 21/89 (23.6%)
Number of 
patients
0
10
20
30
40
50
A B C D E F G H I
Fig. 4　 Decisive treatments and outcomes.  A,  cephems; B,  
ﬂuoroquinolones; C,  penicillins; D,  penems; E,  carbapenems; F,  
minocycline; G,  sulfamethoxazole-trimethoprim; H,  aminoglyco-
sides; I; none.
bars: cure,　　　 light symptom,　　　 no change, 
　　 naturally disappeared,　　　 unclear.
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5 (31.3ｵ) of these patients.
　 There were 2 strains of ﬂuoroquinolone-insuscep-
tible E. coli for which the sitaﬂoxacin MICs were 
2µg/ml (Table 3).  One of these strains was isolated 
from a patient with uncomplicated UTI in 2007,  and 
the other strain was isolated from a patient with 
complicated UTI in 2002.  The underlying disease of 
the complicated UTI case was neurogenic bladder,  and 
urethral catheterization or clean intermittent self-
catheterization was not performed.  The uncompli-
cated UTI case had not been administered any antimi-
crobial agents,  including ﬂuoroquinolones,  prior to the 
bacterial isolation.  However,  the complicated UTI 
case had been administered levoﬂoxacin within 1 week 
prior to the bacterial isolation.  These 2 patients were 
both treated with cefcapene pivoxil HCl and were 
cured.
　 Amino acid replacements in type II topoi-
somerases. Amino acid replacements were exam-
ined in the randomly selected 9 strains of ﬂuoroqui-
nolone-susceptible E. coli and 78 strains of 
ﬂuoroquinolone-insusceptible E. coli.  In a GyrA sub-
unit of DNA gyrase and a ParC subunit of topoi-
somerase IV,  amino acid replacements tended to be 
localized at speciﬁc sites.  Namely,  replacement pat-
terns were frequently seen in which there were substi-
tutions of: serine (Ser) to leucine (Leu) at position 83 
(Ser-83-Leu) in GyrA,  aspartic acid (Asp) to asparag-
ine (Asn) or glycine (Gly) at position 87 (Asp-87-
Asn/Gly) in GyrA,  serine (Ser) to isoleucine (Ile) or 
arginine (Arg) at position 80 (Ser-80-Ile/Arg) in 
ParC,  and glutamic acid (Glu) to valine (Val) or other 
amino acids at position 84 (Glu-84-Val/Others) in 
ParC.  In GyrA,  Ser-83-Leu was observed in 78 of 78 
strains (100ｵ) and Asp-87-Asn/Gly in 77 of 78 
strains (98.7ｵ).  In ParC,  Ser-80-Ile/Arg was 
observed in 73 of 78 strains (93.6ｵ) and Glu-84-Val/
Others in 44 of 78 strains (56.4ｵ).  The replacement 
at position 84 in ParC was a substitution to: valine in 
31 of 44 strains (70.5ｵ),  glycine in 5 strains (11.4ｵ),  
alanine in 4 strains (9.1ｵ),  and lysine in 4 strains 
(9.1ｵ).  There was no clear correlation between the 
number of amino acid replacements at these 4 posi-
tions and oﬂoxacin MIC.  Of 78 strains,  75 had amino 
acid replacements at 3 or more of the aforementioned 
4 positions.  In addition,  73 of 78 strains (93.6ｵ) had 
replacements at 3 positions: positions 83 and 87 in 
GyrA and position 80 in ParC (Table 4).
　 Among the 9 control strains of ﬂuoroquinolone-
susceptible E. coli,  5 strains (55.6ｵ) did not have 
replacements at any of the aforementioned 4 positions.  
There were 2 strains (22.2ｵ) with a replacement of 1 
out of 4 positions,  another 2 strains (22.2ｵ) with 
replacements of 2 positions,  and no strain with 
replacement of 3 positions or more (Table 4).  When 
the 2 E. coli strains in which the sitaﬂoxacin MICs 
were 2µg/ml were examined,  both strains had amino 
acid replacements at 3 positions (Ser-83-Leu and Asp-
87-Asn/Gly in GyrA,  and Ser-80-Ile/Arg in ParC) 
(Table 3).
　 Bioﬁlm-forming capabilities testing. The 
bioﬁlm-forming capabilities of 81 strains of ﬂuoroqui-
nolone-insusceptible E. coli and 40 strains of ﬂuoro-
quinolone-susceptible E. coli were examined using the 
Mann-Whitney U test.  As shown in Fig.  5A,  there 
was no statistically signiﬁcant diﬀerence in the bio-
ﬁlm-forming capabilities between ﬂuoroquinolone-
insusceptible and susceptible E. coli (p＝0.19).  It is 
noteworthy that there were 2 ﬂuoroquinolone-insus-
ceptible strains in which the bioﬁlm-forming capabili-
ties were markedly stronger.  One of these strains was 
isolated from a 70-year-old male with benign prostatic 
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Table 3　 Backgrounds of the patients with UTI due to ﬂuoroquinolone-insusceptible E. coli
Year Sex Age Underlying diseases BioﬁlmOD570
Major amino acid  
replacements MIC (µg/ml)
GyrA ParC Oﬂoxacin Sitaﬂoxacin Levoﬂoxacin
A 2002 F 77 Neurogenic bladder 0 S83L, D87G S80R 128 2 1282007 F 71 None 0.073 S83L, D87N S80I  64 2 16
B 1998 F 18 Urethral stricture 0.783 S83L  32 ｦ0.5 162006 M 70 Bladder stone 2.673 S83L, D87N S80I, E84V 　8 ｦ0.5 4
A: Two strains of E. coli which MIC of sitaﬂoxacin was 2µg/ml.
B: Two strains of E. coli with strong capabilities of bioﬁlm formation.
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hyperplasia,  bladder stone,  and a history of urethral 
catheterization.  The other strain was isolated from an 
18-year-old female without an underlying disease but 
who had repeated bouts of UTI treated with antimi-
crobial agents (Table 3).
　 The 2 strains of E. coli with sitaﬂoxacin MICs of 
2µg/ml had weak bioﬁlm-forming capabilities.  The 77 
strains with sitaﬂoxacin MICs ofｦ1µg/ml were 
divided into a group with MICs ofｦ0.5µg/ml (64 
strains) and a group with a MIC of 1µg/ml (13 
strains).  There was no statistically signiﬁcant diﬀer-
ence between these 2 groups (p＝0.93) (Fig.  5B).
Discussion
　 Eighty-nine strains of ﬂuoroquinolone-insusceptible 
E. coli were isolated at our department in a 14-year 
period between 1994 and 2007,  and we examined 
these strains in the present study.  A total of 82 of the 
89 strains (92.1ｵ) were isolated from complicated 
UTIs.  There were 15 and 16 strains of ﬂuoroqui-
nolone-insusceptible E. coli isolated in 2006 and 2007,  
respectively.  The percentages of ﬂuoroquinolone-
insusceptible E. coli strains relative to the total iso-
lated E. coli strains from the respective years were 
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Fig. 5　 Bioﬁlm-forming capabilities of E. coli strains.  A,  Group I is ﬂuoroquinolone-insusceptible E. coli (mean±SD: 0.084±0.314).  
Group II is ﬂuoroquinolone-susceptible E. coli (mean±SD: 0.029±0.050).  The p-value was 0.19; B,  Group III is ﬂuoroquinolone-insus-
ceptible E. coli strains for which the MICs of sitaﬂoxacin were 0.5µg/ml (mean±SD: 0.024±0.345).  Group IV is ﬂuoroquinolone-insus-
ceptible E. coli strains for which the MICs of sitaﬂoxacin were over 1µg/ml (mean±SD: 0.029±0.045).  The p-value was 0.93.
Table 4　 Correlations between amino acid replacements and MICs of oﬂoxacin
GyrA
(83,  87)
ParC
(80,  84)
MICs of oﬂoxacin (μg/ml)
0.5 2 4 8 16 32 64 128 256
Susceptible Insusceptible
(－,  －) (－,  －) 4 1 0 0 0 0 0 0 0
(＋,  －) (－,  －) 0 2 0 0 0 1 0 0 0
(＋,  －) (－,  ＋) 0 2 0 0 0 0 0 0 0
(＋,  ＋) (－,  －) 0 0 0 1 1 0 0 0 0
(＋,  ＋) (－,  ＋) 0 0 0 1 0 1 0 0 0
(＋,  ＋) (＋,  －) 0 0 3 5 9 8 5 0 1
(＋,  ＋) (＋,  ＋) 0 0 0 14 17 7 4 0 0
Total number of strain
4 5 3 21 27 17 9 0 1
9 78
7
Wada et al.: Experimental and Clinical Studies on Fluoroquinolone-insusceptibl
Produced by The Berkeley Electronic Press, 2009
22ｵ and 19ｵ,  respectively.  The isolation frequency 
of ﬂuoroquinolone-insusceptible E. coli and its percent-
age of the total E. coli isolated tended to increase 
annually.  The results reaﬃrmed that it is important to 
elucidate the mechanism of ﬂuoroquinolone resistance 
and to select eﬀective drugs for treatments.
　 Many reports have indicated that the widespread 
use of ﬂuoroquinolones is contributing to the increas-
ing percentages of ﬂuoroquinolone-insusceptible bacte-
rial strains,  including E. coli [10,  11].  In our exami-
nation of the clinical backgrounds of patients,  we 
found that there were a large number of patients who 
were administered ﬂuoroquinolones in the past.  We 
cannot rule out the possibility that the administration 
of ﬂuoroquinolones had caused a selection for ﬂuoro-
quinolone-insusceptible E. coli,  which would have 
survived and been more frequently isolated.  In recent 
years,  ﬂuoroquinolone-insusceptible E. coli accounted 
for approximately 10ｵ of the total E. coli strains 
isolated in patients with acute uncomplicated UTI but 
without a history of ﬂuoroquinolone administration.  
Thus the problem is no longer conﬁned to within the 
bodies of individual patients who have taken ﬂuoroqui-
nolone,  or,  indeed,  to within individual hospital sys-
tems,  but rather is now of a wider scope.  As the 
problem grows,  we are confronted not only with the 
challenge of decreasing the rate of resistance by 
reducing the use of ﬂuoroquinolones but also of treat-
ing the UTI caused by ﬂuoroquinolone-insusceptible E. 
coli.
　 The antimicrobial eﬀect of ﬂuoroquinolones results 
from the inhibition of type II topoisomerases [12].  
The type II topoisomerases include DNA gyrase,  
which is composed of GyrA and GyrB subunits,  and 
topoisomerase IV,  which is composed of ParC and 
ParE subunits.  DNA gyrase is an enzyme essential for 
the replication of DNA [13].  Topoisomerase IV is an 
enzyme which separates the DNA chains after replica-
tion [14].  In E. coli,  GyrA is the primary site of 
action of ﬂuoroquinolones and ParC is the secondary 
site [15].  One cause of quinolone resistance in E. coli 
is the mutations in the QRDRs of DNA gyrase and 
topoisomerase IV [5,  6].  It is known that double 
replacements in GyrA and one replacement in ParC 
result in a high resistance to ﬂuoroquinolones [16].  
In our study using clinically isolated strains from 
UTIs,  we found amino acid replacements in 3 or more 
positions of the QRDRs of ﬂuoroquinolone-insuscepti-
ble E. coli.  This result was consistent with the ﬁndings 
of Lindgren et al.  obtained using clinically isolated 
strains [17],  and it reconﬁrmed that the mutations in 
the QRDRs were strongly involved in the quinolone 
resistance mechanism.  In the present study,  however,  
there was no apparent correlation between oﬂoxacin 
MIC and the number of amino acid replacements in the 
QRDRs.  The mechanism of E. coli quinolone resis-
tance could not be explained solely by amino acid 
replacements in the QRDRs of type II topoisomerases.  
Other mechanisms of resistance were thought to be 
involved,  such as limited entrance of antimicrobial 
agents into the bacteria due to decreased cell envelope 
permeability and export of antimicrobial agents out of 
the bacteria by multi-drug eﬄux pumps [18-20].  In 
recent years,  there have been many reports on other 
factors that may contribute to resistance such as 
plasmid transmission of resistance [21-23].
　 One of the ﬂuoroquinolones,  sitaﬂoxacin,  has 
stronger inhibitory activities against DNA gyrase and 
topoisomerase IV compared to conventional ﬂuoroqui-
nolones,  and sitaﬂoxacin has been shown to have a 
stronger bactericidal eﬀect [24].  In a pharmacoki-
netic study of sitaﬂoxacin,  this ﬂuoroquinolone 
reached a maximum drug concentration (Cmax) at 1.2 to 
2.0h after administration.  When a single dose of 
100mg was administered postprandially,  it reached a 
Cmax of 0.88±0.31µg/ml [25].  There have been no 
reports on tissue distribution in the prostate and 
epididymis.  However,  sitaﬂoxacin can be said to be an 
eﬀective antimicrobial agent for UTIs,  particularly 
for UTIs whose causative agent is ﬂuoroquinolone-
insusceptible E. coli,  and 70ｵ to 80ｵ of the adminis-
tered sitaﬂoxacin is excreted in urine.  When we 
examined the E. coli strains which were isolated from 
clinical samples at our facility,  the MICs of sitaﬂoxa-
cin tended to correlate with those of other ﬂuoroqui-
nolones.  The sitaﬂoxacin MICs wereｦ2µg/ml for all 
strains,  and wereｦ1µg/ml in over 90ｵ of the 
strains.  These results indicated a very good suscepti-
bility.  In this present study,  we did not observe any 
E. coli strains which showed strong resistance to 
sitaﬂoxacin.  This result suggests that amino acid 
replacements in the QRDRs do not necessarily con-
tribute to the change in the sitaﬂoxacin MIC for E. 
coli.  In addition,  we found that resistance mechanisms 
other than mutations in the QRDRs may play a role in 
increasing the MIC,  although,  if so,  their contribu-
270 Acta Med.  Okayama　Vol.  63,  No.  5Wada et al.
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tion is likely to be small.
　 As in the case of other ﬂuoroquinolones,  the sus-
ceptibility to sitaﬂoxacin could decrease due to its 
overuse.  Under special conditions of complicated 
UTIs (for example,  when a bioﬁlm forms on a ure-
thral catheter or on the surface of a bladder stone),  E. 
coli in the deep layer of the bioﬁlm is exposed to low 
concentrations of sitaﬂoxacin.  Thus,  gene mutations 
could occur and some type of resistant bacteria could 
appear.  In this present study,  29 of 89 strains 
(32.6ｵ) of ﬂuoroquinolone-insusceptible E. coli were 
isolated from UTI patients who had “foreign bodies” in 
their urinary tracts,  such as urethral catheters and 
stones.  We found that there was no statistically sig-
niﬁcant diﬀerence in the bioﬁlm-forming capabilities 
between the ﬂuoroquinolone-susceptible and -insus-
ceptible strains.  The 2 strains which had very strong 
bioﬁlm-forming capabilities were ﬂuoroquinolone-in-
susceptible strains.  Although the relationship between 
ﬂuoroquinolone susceptibility and bioﬁlm-forming 
capabilities has not been clariﬁed,  the eﬀectiveness of 
antimicrobial agents against bacteria within the bioﬁlm 
is less than that against free bacteria or bacteria on 
the bioﬁlm surface [26].  Although at this point it is 
only a supposition,  E. coli strains with a strong bio-
ﬁlm-forming capability may gain quinolone resistance 
after exposure to ﬂuoroquinolones.  Further studies 
examining greater numbers of E. coli strains will be 
needed to clarify the relationship between the bioﬁlm-
forming capabilities and quinolone resistance,  namely 
amino acid replacements in the QRDRs.
　 It is important to avoid the overuse of antimicro-
bial agents and to shorten the administration period of 
antimicrobial agents.  Fluoroquinolones are suitable 
for UTIs because they have a broad antimicrobial 
spectrum and a strong antimicrobial activity,  and 
because E. coli is isolated at the highest frequency in 
uncomplicated UTIs and is presumed to be present in 
complicated UTIs as well.  Our present study has 
shown that sitaﬂoxacin was more eﬀective in vitro than 
other ﬂuoroquinolones.  Although its in vivo eﬀects 
must be further examined in future studies,  we must 
remember that overuse of ﬂuoroquinolones accelerates 
the development of resistance to ﬂuoroquinolones.
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